Published in J Radiat Oncol on September 01, 2013
IDO2 in Immunomodulation and Autoimmune Disease. Front Immunol (2014) 0.92
Chloroquine and hydroxychloroquine for cancer therapy. Mol Cell Oncol (2014) 0.88
The management of brain metastases in non-small cell lung cancer. Front Oncol (2014) 0.85
Tryptophan-degrading enzymes in tumoral immune resistance. Front Immunol (2015) 0.84
MRI virtual biopsy and treatment of brain metastatic tumors with targeted nanobioconjugates: nanoclinic in the brain. ACS Nano (2015) 0.82
Aquaporin 3 facilitates chemoresistance in gastric cancer cells to cisplatin via autophagy. Cell Death Discov (2016) 0.78
Tryptophan PET Imaging of the Kynurenine Pathway in Patient-Derived Xenograft Models of Glioblastoma. Mol Imaging (2016) 0.78
Chloroquine is a zinc ionophore. PLoS One (2014) 0.75
Importance of ROS-mediated autophagy in determining apoptotic cell death induced by physapubescin B. Redox Biol (2017) 0.75
Targeting autophagy in cancer. Nat Rev Cancer (2017) 0.75
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys (1997) 8.58
Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys (2009) 6.11
Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res (2011) 5.40
Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest (2007) 5.05
Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys (1999) 4.72
Brain metastases: epidemiology and pathophysiology. J Neurooncol (2005) 3.83
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res (2007) 3.44
Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med (2006) 3.33
Distribution of brain metastases. Arch Neurol (1988) 3.11
Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys (1999) 2.84
Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res (2007) 2.78
IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov (2012) 2.56
Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev (2008) 2.47
Brain metastases. Histology, multiplicity, surgery, and survival. Cancer (1996) 2.31
Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol (2005) 1.83
Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol (2002) 1.79
A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104. Int J Radiat Oncol Biol Phys (1997) 1.72
Unexpected skin reaction induced by radiotherapy after chloroquine use. Lancet Oncol (2006) 1.71
A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int J Radiat Oncol Biol Phys (1991) 1.63
Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol (2012) 1.53
A validation study of a new prognostic index for patients with brain metastases: the Graded Prognostic Assessment. J Neurosurg (2008) 1.48
Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: report of RTOG trial 89-05. Int J Radiat Oncol Biol Phys (1995) 1.46
Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. Neuro Oncol (2010) 1.33
Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys (2008) 1.33
Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys (1981) 1.28
Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme. Surg Neurol (2007) 1.13
Long-term survival in patients with brain metastases. J Cancer Res Clin Oncol (2002) 1.02
The combined use of radiation therapy and lonidamine in the treatment of brain metastases. J Neurooncol (1989) 0.97
Results of a randomized clinical trial comparing two radiation schedules in the palliative treatment of brain metastases. Radiother Oncol (1993) 0.93
Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases. Am J Clin Oncol (2007) 0.92
Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment metastatic cancer to brain. A Southwest Oncology Group study. J Neurooncol (1984) 0.91
American College of Radiology appropriateness criteria on multiple brain metastases. Int J Radiat Oncol Biol Phys (2009) 0.91
Neurologic complications of systemic cancer. Dis Mon (1978) 0.89
DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide. Biochem Pharmacol (1997) 0.89
A phase III study of accelerated versus conventional hypofractionated whole brain irradiation in patients of good performance status with brain metastases not suitable for surgical excision. Radiother Oncol (2008) 0.87
pH-dependent regulation of camptothecin-induced cytotoxicity and cleavable complex formation by the antimalarial agent chloroquine. Biochem Pharmacol (1997) 0.83
Unusual intensification of skin reactions by chloroquine use during breast radiotherapy. Acta Oncol (2008) 0.77
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med (2005) 4.92
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res (2007) 3.44
Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood (2009) 2.88
Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res (2007) 2.78
Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation (2011) 2.61
IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov (2012) 2.56
Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev (2008) 2.47
Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci U S A (2008) 2.18
RhoB and actin polymerization coordinate Src activation with endosome-mediated delivery to the membrane. Dev Cell (2004) 2.13
Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets (2007) 1.86
Opposing biological functions of tryptophan catabolizing enzymes during intracellular infection. J Infect Dis (2011) 1.86
Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J Med Chem (2006) 1.81
RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development. Genes Dev (2003) 1.48
Genetic response to farnesyltransferase inhibitors: proapoptotic targets of RhoB. Cancer Biol Ther (2003) 1.46
Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology (2002) 1.41
Bin1 attenuation suppresses experimental colitis by enforcing intestinal barrier function. Dig Dis Sci (2012) 1.40
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol Immunother (2014) 1.39
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology (2012) 1.37
Cyclin D1 functions in cell migration. Cell Cycle (2006) 1.36
The crystal structure of the BAR domain from human Bin1/amphiphysin II and its implications for molecular recognition. Biochemistry (2006) 1.35
The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J Immunol (2009) 1.34
Targeted disruption of the murine Bin1/Amphiphysin II gene does not disable endocytosis but results in embryonic cardiomyopathy with aberrant myofibril formation. Mol Cell Biol (2003) 1.26
Alternate cyclin D1 mRNA splicing modulates p27KIP1 binding and cell migration. J Biol Chem (2008) 1.25
Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway. Am J Pathol (2010) 1.24
Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. J Immunol (2010) 1.22
Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem (2008) 1.18
Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol Cancer Ther (2002) 1.18
Amino acid catabolism: a pivotal regulator of innate and adaptive immunity. Immunol Rev (2012) 1.16
Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg (2009) 1.11
Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer. Cancer Res (2007) 1.10
Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem (2008) 1.07
Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate. Cancer Res (2010) 1.06
Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunol Immunother (2010) 1.04
Marrying immunotherapy with chemotherapy: why say IDO? Cancer Res (2005) 1.04
Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin Ther Targets (2005) 1.02
RhoB regulates PDGFR-beta trafficking and signaling in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2007) 1.02
Role of RhoB in the regulation of pulmonary endothelial and smooth muscle cell responses to hypoxia. Circ Res (2012) 1.01
Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. Clin Cancer Res (2003) 1.00
Cancer: Why tumours eat tryptophan. Nature (2011) 0.99
Ventricular transmural repolarization sequence: its relationship with ventricular relaxation and role in ventricular diastolic function. Eur Heart J (2009) 0.99
IDO recruits Tregs in melanoma. Cell Cycle (2009) 0.98
Randomized controlled trial of illness management and recovery in multiple-unit supportive housing. Psychiatr Serv (2009) 0.97
Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes. Cancer Res (2011) 0.97
Reduction of hepatitis C virus NS5A phosphorylation through its interaction with amphiphysin II. Biochem Biophys Res Commun (2005) 0.96
Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors. Oncogene (2003) 0.96
AACR Cancer Progress Report 2013. Clin Cancer Res (2013) 0.95
Vascular endothelial growth factor receptor-2 expression is down-regulated by 17beta-estradiol in MCF-7 breast cancer cells by estrogen receptor alpha/Sp proteins. Mol Endocrinol (2007) 0.94
Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase. Mol Cancer Ther (2010) 0.94
Bin3 deletion causes cataracts and increased susceptibility to lymphoma during aging. Cancer Res (2008) 0.93
A role for RhoB in synaptic plasticity and the regulation of neuronal morphology. J Neurosci (2010) 0.93
Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation. Immunotherapy (2010) 0.91
RhoB links PDGF signaling to cell migration by coordinating activation and localization of Cdc42 and Rac. J Cell Biochem (2011) 0.90
Endometrial cancer surgery costs: robot vs laparoscopy. J Minim Invasive Gynecol (2010) 0.90
The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells. J Immunol (2014) 0.89
Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase. Cancer Biol Ther (2011) 0.89
Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. Cancer Res (2002) 0.89
Immunohistochemical analysis of Bin1/Amphiphysin II in human tissues: diverse sites of nuclear expression and losses in prostate cancer. J Cell Biochem (2003) 0.89
Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression. Cancer Res (2007) 0.89
Molecular characterization of two superoxide dismutases from Hydra vulgaris. Gene (2006) 0.87
Use of dabigatran etexilate to reduce breast cancer progression. Cancer Biol Ther (2010) 0.86
Bin1 attenuation in breast cancer is correlated to nodal metastasis and reduced survival. Cancer Biol Ther (2007) 0.86
RhoB differentially controls Akt function in tumor cells and stromal endothelial cells during breast tumorigenesis. Cancer Res (2012) 0.85
A perspective on new immune adjuvant principles: Reprogramming inflammatory states to permit clearance of cancer cells and other age-associated cellular pathologies. Oncoimmunology (2012) 0.84
Is there a role for MRI in the preoperative assessment of patients with DCIS? Ann Surg Oncol (2010) 0.84
RhoB controls coordination of adult angiogenesis and lymphangiogenesis following injury by regulating VEZF1-mediated transcription. Nat Commun (2013) 0.84
The microculture-kinetic (MiCK) assay: the role of a drug-induced apoptosis assay in drug development and clinical care. Cancer Res (2012) 0.84
Correlation of drug-induced apoptosis assay results with oncologist treatment decisions and patient response and survival. Cancer (2012) 0.84
Correlation of the microculture-kinetic drug-induced apoptosis assay with patient outcomes in initial treatment of adult acute myelocytic leukemia. Leuk Lymphoma (2012) 0.84
Hydroxyethyl disulfide as an efficient metabolic assay for cell viability in vitro. Toxicol In Vitro (2012) 0.84
Cyclin B1 is a critical target of RhoB in the cell suicide program triggered by farnesyl transferase inhibition. Cancer Res (2004) 0.83
Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma. Radiat Oncol (2011) 0.83
hob1+, the fission yeast homolog of Bin1, is dispensable for endocytosis or actin organization, but required for the response to starvation or genotoxic stress. Oncogene (2003) 0.83
Genetic response to DNA damage: proapoptotic targets of RhoB include modules for p53 response and susceptibility to Alzheimer's disease. Cancer Biol Ther (2005) 0.82
The N-BAR domain protein, Bin3, regulates Rac1- and Cdc42-dependent processes in myogenesis. Dev Biol (2013) 0.82
Genomic profiling of miRNAs in two human lens cell lines. Curr Eye Res (2010) 0.82
Correlation of pretreatment drug induced apoptosis in ovarian cancer cells with patient survival and clinical response. J Transl Med (2012) 0.82
Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1. Oncogene (2003) 0.82
Targeted deletion of the suppressor gene bin1/amphiphysin2 accentuates the neoplastic character of transformed mouse fibroblasts. Cancer Biol Ther (2004) 0.81
Loss of RhoB expression enhances the myelodysplastic phenotype of mammalian diaphanous-related Formin mDia1 knockout mice. PLoS One (2009) 0.81
mDia function is critical for the cell suicide program triggered by farnesyl transferase inhibition. Cancer Biol Ther (2007) 0.80
RhoB loss prevents streptozotocin-induced diabetes and ameliorates diabetic complications in mice. Am J Pathol (2010) 0.79